1-5 of 5
Authors: Kara Davis
Journal Article
IMMU-60. MYELOID POPULATIONS MODULATE GD2 CAR T CELL ACTIVITY IN DIFFUSE MIDLINE GLIOMA Free
Neuro-Oncology, Volume 26, Issue Supplement_8, November 2024, Page viii166, https://doi.org/10.1093/neuonc/noae165.0652
Published: 11 November 2024
Journal Article
IMMU-05. TUMOR INFLAMMATION-ASSOCIATED NEUROTOXICITY (TIAN): A TOXICITY SYNDROME IN PATIENTS TREATED WITH IMMUNOTHERAPY FOR CENTRAL NERVOUS SYSTEM TUMORS Open Access
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i50, https://doi.org/10.1093/neuonc/noad073.192
Published: 12 June 2023
Journal Article
DIPG-15. Major tumor regressions in H3K27M-mutated diffuse midline glioma (DMG) following sequential intravenous (IV) and intracerebroventricular (ICV) delivery of GD2-CAR T-cells Open Access
Neuro-Oncology, Volume 24, Issue Supplement_1, June 2022, Pages i20–i21, https://doi.org/10.1093/neuonc/noac079.072
Published: 03 June 2022
Journal Article
OMIC-11. SINGLE CELL RNA SEQUENCING FROM THE CSF OF SUBJECTS WITH H3K27M+ DIPG/DMG TREATED WITH GD2 CAR T-CELLULAR THERAPY Open Access
Neuro-Oncology, Volume 23, Issue Supplement_1, June 2021, Page i39, https://doi.org/10.1093/neuonc/noab090.158
Published: 01 June 2021
Journal Article
EPCT-14. GD2 CAR T-CELLS MEDIATE CLINICAL ACTIVITY AND MANAGEABLE TOXICITY IN CHILDREN AND YOUNG ADULTS WITH H3K27M-MUTATED DIPG AND SPINAL CORD DMG Open Access
Neuro-Oncology, Volume 23, Issue Supplement_1, June 2021, Pages i49–i50, https://doi.org/10.1093/neuonc/noab090.200
Published: 01 June 2021
